(Q35584206)

English

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

scientific article published on July 29, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study (English)

1 reference

10.1634/THEONCOLOGIST.2009-0029

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2009-0029

13 June 2024

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Anne Vincent-Salomon

3

object named as

Anne Vincent-Salomon

0 references

Jean-Paul Guastalla

7

object named as

Jean-Paul Guastalla

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Jean-Marc Extra

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Thierry Delozier

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Pierre Kerbrat

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Anne Bethune-Volters

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Marc Spielmann

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Louis Mauriac

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jean-Louis Misset

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Daniel Serin

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Mario Campone

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Christophe Hebert

13

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Céline Remblier

14

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Loïc Bergougnoux

15

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Frank Campana

16

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Moïse Namer

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Eric C. Antoine

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20671105

13 June 2024

publication date

29 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

full work available at URL

https://europepmc.org/articles/pmc3228018?pdf=render

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20671105/?tool=EBI

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20671105/pdf/?tool=EBI

Portable Document Format

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

http://intl-theoncologist.alphamedpress.org/cgi/content/full/15/8/799

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

http://intl-theoncologist.alphamedpress.org/cgi/content/abstract/15/8/799

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

http://intl-theoncologist.alphamedpress.org/cgi/reprint/15/8/799.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

https://europepmc.org/articles/PMC3228018

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

https://europepmc.org/articles/PMC3228018?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671105

13 June 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2009-0029

1 reference

10.1634/THEONCOLOGIST.2009-0029

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2009-0029

13 June 2024

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2009-0029

1 reference

10.1634/THEONCOLOGIST.2009-0029

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2009-0029

13 June 2024

https://academic.oup.com/oncolo/article-pdf/15/8/799/41844097/oncolo_15_8_799.pdf

Portable Document Format

1 reference

10.1634/THEONCOLOGIST.2009-0029

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2009-0029

13 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

799-809

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

27 July 2018

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

First--select the target: better choice of adjuvant treatments for breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

Survival after brain metastases from breast cancer in the trastuzumab era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228018

26 September 2018

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20671105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20671105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/20671105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1634/THEONCOLOGIST.2009-0029

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35584206&oldid=2180216260"